The neuroimmune hypothesis in Parkinson's disease

Reviews in the Neurosciences

Volumn 8, Issue 1, 1997, Pages 29-34

  Kuhn, Wilfried ^a   Müller, Thomas ^a   Nastos, Ilias ^a   Poehlau, Dieter ^a  

^a ST JOSEF HOSPITAL   (Germany)

Author keywords

Cytokines; Immune mechanisms; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE;

AUTOIMMUNITY; BRAIN; BRAIN DEGENERATION; DOPAMINERGIC NERVE CELL; HUMAN; IMMUNOPATHOLOGY; PARKINSONISM; PRIORITY JOURNAL; REVIEW;

EID: 0030767945     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.1997.8.1.29     Document Type: Review

References (69)

1. Abb J, Abb H, Deinhard D. Age related decline of interferon alpha and interferon gamma production. Blut 1984; 48: 285.
2. Abramsky O, Litvin J. Autoimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia. Perspect Biol Med 1978; 22: 104-114.
3. Ader R, Cohen N, Felton D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet 1995; 345: 99-103.
4. Appel SH, Le WD, Tajti J, Haverkamp LJ, Engelhardt JI. Nigral damage and dopaminergic hypofunction in mesencephalon-immunized guinea pigs. Ann Neurol 1992; 32: 494-510.
5. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: Selective effects on specific interleukins and interleukin receptors. Neuroscience 1994; 61: 745-754.
6. Araujo DM, Lapchak PA, Collier B, Quirion R. Localisation of interleukin-2 immunoreactivity and interleukin-receptors in the rat brain: Interactions with the cholinergic system. Brain Res 1989; 498: 257-266.
7. Bieganowska K, Czlonkowska A, Bidzinski A, Mierzewska H, Korlak J. Immunological changes in the MPTP-induced Parkinson's disease mouse model. J Neuroimmunol 1993; 42: 33-38.
8. Blum-Degen D, Müller Th, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202: 17-20.
9. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994; 172: 151-154.
10. 2 dopaminergic antagonists on mouse T- and B-lymphocyte proliferation and interleukin production in vitro. Immunpharmacol Immuntoxicol 1988; 10: 501-505.
11. Burakoff SJ, Engelhard VH, Kalfman J, Strominger JL. Induction of secondary cytotoxic T-lymphocytes by liposomes containing HLA-DR antigens. Nature 1980; 283: 495-497.
12. Carpenter G, Cohen S. Epidermal growth factor. Ann RevBiochem 1979; 48: 193-216.
13. Chalazonitis A, Kessler JA, Twardzik DR, Morrison RS. Transforming growth factor α, but not epidermal growth factor, promotes the survival of sensory neurons in vitro. J Neurosci 1992; 12: 583-594.
14. Chronsos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation N Engl J Med 1995; 332: 1351-1362.
15. Defazio G, Dal Tosa R, Benvegnu D, Minozzi MC, Cananzi A, Leon A. Parkinsonian serum carries complement dependent toxicity of rat mesencephalic dopaminergic neurons in culture. Brain Res 1994; 633: 206-212.
16. Deleplanque B, Vitiello S, Le Moal M, Neveu PJ. Modulation of immune reactivity by unilateral striatal and mesolimbic dopaminergic lesions. Neurosci Lett 1994; 166: 216-220.
17. Elizan TS, Madden DL, Noble GR, Herrmann KL, Gardner J, Schwartz J, Smith H, Sever JL, Yahr MD. Viral antibodies in serum and CSF of Parkinsonian patients and controls. Arch Neurol 1979; 36: 529-534.
18. Elizan TS, Schwartz J, Yahr MD, Casals J. Antibodies against Arboviruses in postencephalitic and idiopathic Parkinson's disease. Arch Neurol 1978; 35: 257-260.
19. 3H]-dopamine to human lymphocytes. Possible relationship to neurotransmitter uptake sites. Pharmacology 1991; 42: 135.
20. Ferrari G, Minozzi MC, Toffano G, Leon A, Skaper SD. Basic fibroblast growth factor promotes the survival and development of mesencephalic neurons in culture. Dev Biol 1989; 133: 140-147.
21. + T cells in peripheral blood. Acta Neurol Scand 1994; 90: 160-166.
22. Fiszer U, Piotrowska K, Korlak J, Czlonkowska A. The immunological status in Parkinson's disease. Med Lab Sci 1991; 48: 196-200.
23. Graham DJ, Tiffany SM, Bell WR, Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds towards CL1300 neuroblastoma cells in vitro. Mol Pharmacol 1978; 14: 644-653.
24. Giulian D, Lachman LB. Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 1985; 228: 497-499.
25. Husby G, Li L, Davis L, Wedege E, Kokmen E, Williams RC Jr. Antibodies to human caudate nucleus neurons in Huntington's chorea. J Clin Invest 1977; 59: 922-932.
26. Jansson B, Jankovic J. Low cancer rates among patients with Parkinson's disease. Ann Neurol 1985; 17: 505-509.
27. Jellinger KA. Neurodegenerative disorders with extrapyramidal features - a neuropathological overview. J Neural Transm 1995; 46: S 33-57.
28. Jenner P, Schapira AHV, Marsden CD. New insights in the cause of Parkinson's disease. Neurology 1992; 42: 2241-2250.
29. Kessler I. Epidemiologic studies of Parkinson's disease. A community based survey. Am J Epidemiol 1972; 96: 242-254.
30. Kessler I. Epidemilogic studies of Parkinson's disease. A hospital based survey. Am J Epidemiol 1972; 95: 308-318.
31. Kohbata S, Beaman BL. L-Dopa responsive movement disorder caused by Nocardia asteroides localized in the brain of mice. Infect Immunit 1991; 59: 181-191.
32. Kohbata S, Shimokawa K. Circulating antibody to Nocardia in the serum of patients with Parkinson's disease. Adv Neurol 1993; 60: 355-357.
33. Kohlhepp W, Kuhn W, Krüger H. Extrapyramidal features in central Lyme Borreliosis. Eur Neurol 1989; 29: 150-153.
34. Kondo Y, Imai Y, Hojo H, Endo T, Nozoe S. Suppression of tumor cell growth and mitogen response by aporphine alkaloids, dicentrine, glaucine, corydine and apomorphine. J Pharmcobio-Dyn 1990; 13: 426-429.
35. Kostulas VK, Link H, Lefvert AK. Oligoclonal IgG bands in cerebrospinal fluid. Arch Neurol 1987; 44: 1041-1044.
36. Kuhn W, Martin R, Müller G, Kappos L, Przuntek H. Further characterization of immune function in Parkinson's disease. 9th Int. Symposium on Parkinson's Disease. Jerusalem 1988; 103 [Abstract].
37. Kuperman O, Herishanu Y, Abarbanel J, Rosenberg P. Cellular and humoral immunity in Parkinsonism. J Israel Med Ass 1980; 69: 1-2 [Abstract].
38. Le W, Engelhardt W, Xie W, Appel SH. Immune invasion with serum against DA neurons induces a Parkinsonian model in rats. Mov Disord 1993; 8: S 409 [Abstract].
39. Lindholm D, Heumann R, Meyer M, Thoenen H. Interleukin-1 regulates synthesis of nerve growth factor in non-neuronal cells of rat sciatic nerve. Nature 1987; 330: 658-659.
40. Martilla PJ, Arstila P, Nikoskelaimen J. Viral antibodies in the sera from patients with Parkinson's disease. Eur Neurol 1977; 15: 25-33.
41. Martilla RJ, Eskola J, Paivarinta M, Rinne UK. Immune functions in Parkinson's disease. Adv Neurol 1984; 40: 315-323.
42. Martilla RJ, Eskola J, Soppi E, Rinne UK. Immune functions in Parkinson's disease: Lymphocyte subsets, concavalin A-induced suppressor cell activity and in vitro immunoglobulin production. J Neurol Sci 1985; 69: 121-131.
43. McGeer PL, Hagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-1291.
44. McGeer PL, McGeer E, Walker D. Immune mechanism in neurodegenerative disorders. Mov Disord 1994; S 9: M3 [Abstract].
45. McRaue-Degueurce A, Losengren L, Haglid K, Bööj S, Gottfries CG, Granerus AC, Dahlström A. Immunocytochemical investigations on the presence of neuron specific antibodies in the CSF of Parkinson's disease cases. Neurochem Res 1988; 13: 679-684.
46. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from Parkinsonian patients. Neurosci Lett 1994; 165: 208-210.
47. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T. Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett 1995; 193: 129-132.
48. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T. Interleukin-1β, interleukin 6, epidermal growth factor and transforming growth factor-α, are elevated in the brain from Parkinsonian patients. Neurosci Lett 1994; 180: 147-150.
49. 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm [P-D Sect] 1995; 9: 87-92.
50. Nastos I, Poehlau D, Postert T, Amoiridis G, Przuntek H. Tumor necrosis factor-alpha production of peripheral blood mononuclear cells in Parkinson's disease. J Neurol 1995; 242: S 137-138 [Abstract].
51. Nomoto M, Igata A. Do Parkinsonian patients have a greater resistance to the common cold? J Neurol Neurosurg Psychiatry 1983; 46: 1153-1154.
52. Ovadia H, Abramsky O. Dopamine receptors on isolated membranes of rat lymphocytes. J Neurosci Res 1987; 18:70-76.
53. Poehlau D, Baier JE, Kovacs S, Gallati H, Suchy I, Will C, Schmutz T, Neumann HA, Przuntek H. Is dopaminergic therapy immunologically rejuvenating? Increased interferon-gamma production with the dopaminergic agent lisuride. Fortschritte der Medizin 1994; 112: 174-176.
54. Renoux G, Bizierre K. Neocortex lateralization of immune function. In: Ader R, Cohen N, Felton DL, eds, Psychoneuroimmunology. New York: Academic Press 1991; 127-148.
55. Richter RW, Silva M, Neu HC, Silverstein PM. The neurological aspects of Nocardia asteroides infection. Res Publ Assoc Nerv Ment Dis 1964; 44: 424-444.
56. Riederer P, Lange KW. Pathogenesis of Parkinson's disease. Curr Opin Neurol Neurosurg 1992; 5: 295-300.
57. Robbins DS, Shirazi Y, Drysdale BE, Lieberman A, Shin HS, Shin ML. Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes. J Immunol 1987; 139: 2593-2597.
58. Roberts AB, Sporn MB. Mini review, physiological actions and clinical applications of transforming growth factor-β. Growth Factors 1993; 8: 1-9.
59. Rogers J, Luber-Narod J. Immune actions in the nervous system: A brief review with special emphasis on Alzheimer's disease. Drug Devel Res 1988; 15: 227-235.
60. Sasco JA, Pfaffenberger RS. Measles infections and Parkinson's disease. Am J Epidemiol 1985; 122: 1017-1031.
61. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 1989; 491: 394-397.
62. Schwartz J, Elizan TS. Search for viral particles and virus specific products in idiopathic Parkinson disease brain material. Ann Neurol 1979; 6: 261-263.
63. Tooyama I, Kawamata T, Walker D, Yamada T, Hanai K, Kimura H, Iwane M, Igarashi K, McGeer ED, McGeer PL. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease. Neurology 1993; 43: 372-376.
64. Vassalli P. Tumor necrosis factor: knock out but not knocked out. Current Biol 1993; 3: 607-610.
65. Wang J, Bankiewicz KS, Plunkett PJ, Oldfield EH. Intrastriatal implantation of interleukin-1. J Neurosurg 1994; 80: 484-490.
66. Wick MM. Dopamine a novel antitumor agent active against B-16 melanoma in vivo. J Invest Dermatol 1978; 71: 163-164.
67. Williams A, Houff S, Lees A, Calne DB. Oligoclonal banding in the cerebrospinal fluid of patients with post-encephalitic Parkinsonism. J Neurol Neurosurg Psychiatry 1979; 42: 790-792.
68. Yamada T, McGeer PL, McGeer EG. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 1992; 84: 100-104.
69. Ziv I, Nardi N, Luria D, Achiron A, Offen D, Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 1994; 170: 136-140.